

**Reference Number:** FOI202223/192  
**From:** Private Individual  
**Date:** 22 August 2022  
**Subject:** Use of medications in treatment of immune thrombocytopenia

**Q1** How many patients has your trust treated (for any disease) in the last 6 months (or the latest 6 months data you have available) with the treatments listed below:

- a. Revolade (eltrombopag)
- b. Nplate (romiplostim)
- c. Doptelet (avatrombopag)
- d. Tavlesse (fostamatinib)

**A1** Zero

**Q2** In the last 6 months (or the latest 6 months data you have available), how many patients has your trust treated for immune thrombocytopenia (ITP)?

**A2** Zero

**Q3** Of the patients treated for immune thrombocytopenia (ITP) in the last 6 months (or the latest 6 months data you have available), how many were treated with:

- a. rituximab
- b. mycophenolate mofetil
- c. surgery (splenectomy)

**A3** Information not held – Not applicable as per A2

**Q4** Does your trust participate in any ongoing clinical trials for immune thrombocytopenia (ITP)? If so, can you please provide the name of each trial along with the number of patients taking part?

**A4** Information not held – The Trust is not involved in any clinical trials for ITP